Cycloheptanamine

Cycloheptanamine

SCHEMBL720218

NC1CCCCCC1.O=C(O)O

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Cycloheptanamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
ALDH1A1 P00352 2/20 0.42
MMP8 P22894 2/20 0.41
MMP1 P03956 1/20 0.41
EPHX1 P07099 6/20 0.40
MMP2 P08253 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 1/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP3A4 P08684 1/20 0.38
EPHX2 P34913 1/20 0.38
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclooctanamine SCHEMBL11193013 1.00 CES2 (0.43) CES2CES1ALDH1A1MMP8MMP1
Cyclohexylamine SCHEMBL578785 1.00 CES2 (0.43) CES2CES1ALDH1A1MMP8MMP1
Cyclohexylamine SCHEMBL974340 1.00 CES2 (0.43) CES2CES1ALDH1A1MMP8MMP1
Cyclopentanamine SCHEMBL578697 0.97 THRB (0.39) CES2CES1ALDH1A1MMP8MMP1
Cyclohexylamine SCHEMBL27712727 0.94 ALDH1A1 (0.39) CES2CES1ALDH1A1MMP8MMP1
Cyclohexylamine SCHEMBL669342 0.91 CES2 (0.41) CES2CES1ALDH1A1MMP8MMP1
Cyclohexylamine SCHEMBL27724093 0.91 CES2 (0.41) CES2CES1ALDH1A1MMP8MMP1
Cyclohexylamine SCHEMBL11585174 0.91 EPHX1 (0.44) CES2CES1ALDH1A1MMP8MMP1
Cyclohexylamine SCHEMBL974731 0.91 EPHX1 (0.44) CES2CES1ALDH1A1MMP8MMP1
Cyclohexylamine SCHEMBL28119655 0.91 EPHX1 (0.44) CES2CES1ALDH1A1MMP8MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765408-B1 POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY NOVO NORDISK AS (DK) 2015-12-09 EP claimed
EP-2289560-B1 POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY NOVO NORDISK AS (DK) 2015-04-22 EP claimed
EP-0606881-B1 Cyclic pentapeptides having a beta-turn and a gamma-turn TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1999-05-12 EP claimed
US-8586638-B2 Parakeratosis inhibitor and skin preparation for external use SHISEIDO COMPANY, LTD (JP) 2013-11-19 US disclosed
US-20120253064-A1 PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE SHISEIDO COMPANY, LTD. (JP) 2012-10-04 US disclosed
EP-2491980-A2 Parakeratosis inhibitor and skin preparation for external use SHISEIDO COMPANY LIMITED (JP) 2012-08-29 EP disclosed
EP-2491981-A2 Parakeratosis inhibitor and external composition for skin SHISEIDO COMPANY LIMITED (JP) 2012-08-29 EP disclosed
US-20120053243-A1 PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE SHISEIDO COMPANY, LTD. (JP) 2012-03-01 US disclosed
EP-1902037-B1 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2009-09-02 EP disclosed
EP-1902037-A1 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS Boehringer Ingelheim International GmbH (DE) 2008-03-26 EP disclosed
US-20070225380-A1 Parakeratosis Inhibitor and Skin Preparation for External use SHISEIDO COMPANY LTD. (JP) 2007-09-27 US disclosed
WO-2007003596-A1 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-01-11 WO disclosed
EP-1688126-A1 PARAKERATOSIS INHIBITOR AND EXTERNAL COMPOSITION FOR SKIN SHISEIDO COMPANY LIMITED (JP) 2006-08-09 EP disclosed
EP-0640618-B1 Tetrahydronaphthalene-peptide derivatives HOFFMANN LA ROCHE (CH) 1999-10-20 EP disclosed
EP-0729972-A1 Peptide derivatives of tetrahydronaphthalene F. HOFFMANN-LA ROCHE AG (CH) 1996-09-04 EP disclosed
EP-0640618-A1 Tetrahydronaphthalene-peptide derivatives F. HOFFMANN-LA ROCHE AG (CH) 1995-03-01 EP disclosed
EP-0592791-A2 Tricyclic compounds and peptide derivatives thereof F. HOFFMANN-LA ROCHE AG (CH) 1994-04-20 EP disclosed
EP-0068373-A1 Schiff bases of aminocycloalcanecarboxylic esters, preparation thereof and use thereof as intermediate products BASF Aktiengesellschaft (DE) 1983-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053243-A1 PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE CUTA, HPN, DNPEP CES2 4196/4885CES1 3419/4885ALDH1A1 3008/4885
US-20120253064-A1 PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE CUTA, HPN, PRSS1 CES2 4452/4885CES1 3552/4885ALDH1A1 3879/4885
US-20070225380-A1 Parakeratosis Inhibitor and Skin Preparation for External use CUTA, HPN, DNPEP CES2 4196/4885CES1 3419/4885ALDH1A1 3008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.